Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)

Authors:

Abstract
No abstract available
Funding Information
  • Takeda Pharmaceutical Company
  • National Institutes of Health
  • AstraZeneca
  • Life Sciences, University of California, Los Angeles
  • Breast Cancer Research Foundation

This publication has 35 references indexed in Scilit: